GoodRx (NASDAQ:GDRX) Shares Up 5.5% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price was up 5.5% during mid-day trading on Wednesday . The company traded as high as $4.65 and last traded at $4.73. Approximately 100,978 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 1,326,227 shares. The stock had previously closed at $4.48.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GDRX shares. Wells Fargo & Company dropped their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target for the company. KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Morgan Stanley decreased their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.18.

GoodRx Stock Performance

The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -158.83, a PEG ratio of 2.46 and a beta of 1.25. The company has a fifty day moving average of $4.72 and a two-hundred day moving average of $5.46. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Institutional Trading of GoodRx

Several hedge funds have recently added to or reduced their stakes in GDRX. Point72 Asset Management L.P. acquired a new stake in GoodRx during the 3rd quarter worth approximately $11,295,000. Clearbridge Investments LLC acquired a new position in GoodRx in the 4th quarter valued at $5,863,000. Rubric Capital Management LP raised its holdings in GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after acquiring an additional 943,226 shares in the last quarter. Franklin Resources Inc. acquired a new position in GoodRx in the 3rd quarter valued at $5,675,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in GoodRx by 303.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock valued at $4,936,000 after acquiring an additional 798,261 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.